MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space

  • Post author:
  • Post category:uncategorized

Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients.